JP2025503177A5 - - Google Patents

Info

Publication number
JP2025503177A5
JP2025503177A5 JP2024544414A JP2024544414A JP2025503177A5 JP 2025503177 A5 JP2025503177 A5 JP 2025503177A5 JP 2024544414 A JP2024544414 A JP 2024544414A JP 2024544414 A JP2024544414 A JP 2024544414A JP 2025503177 A5 JP2025503177 A5 JP 2025503177A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
day
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503177A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/052005 external-priority patent/WO2023144306A1/en
Publication of JP2025503177A publication Critical patent/JP2025503177A/ja
Publication of JP2025503177A5 publication Critical patent/JP2025503177A5/ja
Pending legal-status Critical Current

Links

JP2024544414A 2022-01-28 2023-01-27 びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体 Pending JP2025503177A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304422P 2022-01-28 2022-01-28
US63/304,422 2022-01-28
PCT/EP2023/052005 WO2023144306A1 (en) 2022-01-28 2023-01-27 Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma

Publications (2)

Publication Number Publication Date
JP2025503177A JP2025503177A (ja) 2025-01-30
JP2025503177A5 true JP2025503177A5 (cg-RX-API-DMAC7.html) 2026-02-10

Family

ID=85158380

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544414A Pending JP2025503177A (ja) 2022-01-28 2023-01-27 びまん性大細胞型b細胞リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体

Country Status (11)

Country Link
US (2) US20230303693A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469083A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025503177A (cg-RX-API-DMAC7.html)
KR (1) KR20240144239A (cg-RX-API-DMAC7.html)
CN (1) CN118647402A (cg-RX-API-DMAC7.html)
AU (1) AU2023213099A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243347A1 (cg-RX-API-DMAC7.html)
IL (1) IL314341A (cg-RX-API-DMAC7.html)
MX (1) MX2024008832A (cg-RX-API-DMAC7.html)
TW (1) TW202345905A (cg-RX-API-DMAC7.html)
WO (1) WO2023144306A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IN2014CN03887A (cg-RX-API-DMAC7.html) 2011-10-27 2015-10-16 Genmab As
KR102813816B1 (ko) 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
BR112020015052A2 (pt) 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
WO2022053654A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma

Similar Documents

Publication Publication Date Title
JP2023541860A5 (cg-RX-API-DMAC7.html)
JP2023542289A5 (cg-RX-API-DMAC7.html)
JP2023542290A5 (cg-RX-API-DMAC7.html)
JP2023541858A5 (cg-RX-API-DMAC7.html)
JP2023517236A5 (cg-RX-API-DMAC7.html)
JP2023524149A5 (cg-RX-API-DMAC7.html)
JP2023542092A5 (cg-RX-API-DMAC7.html)
JP2023542291A5 (cg-RX-API-DMAC7.html)
JP2023002615A5 (cg-RX-API-DMAC7.html)
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP6278536B2 (ja) 関節炎治療
RU2017121327A (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2021512107A5 (cg-RX-API-DMAC7.html)
JP2022512875A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
IL255552A (en) Treatment of multiple myeloma
JP2024069230A5 (cg-RX-API-DMAC7.html)
WO2017059813A1 (zh) 抗乙肝表面抗原的抗体及其用途
JP2025508317A5 (cg-RX-API-DMAC7.html)
JP2024540435A5 (cg-RX-API-DMAC7.html)
JP2020505350A5 (cg-RX-API-DMAC7.html)
JP2024527401A5 (cg-RX-API-DMAC7.html)
JP2025503176A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)